GSK plc (GSK)
| Market Cap | 97.52B +18.5% |
| Revenue (ttm) | 44.05B +5.0% |
| Net Income | 6.40B +40.8% |
| EPS | 3.13 +42.6% |
| Shares Out | 4.01B |
| PE Ratio | 15.25 |
| Forward PE | 9.65 |
| Dividend | $1.79 (3.66%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 1,289,365 |
| Open | 48.82 |
| Previous Close | 48.54 |
| Day's Range | 48.60 - 49.16 |
| 52-Week Range | 39.29 - 61.70 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 58.58 (+20.08%) |
| Earnings Date | Oct 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $58.58, which is an increase of 20.08% from the latest price.
News
GSK plc Transcript: Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference
Leadership is accelerating R&D and simplifying operations, driving GBP 2 billion in savings to fund a robust pipeline, including HIV long-acting injectables, oncology, and liver disease innovations. Commercial execution and specialty focus support margin stability through key patent expiries.
GSK initiated with a Sector Perform at RBC Capital
RBC Capital analyst Trung Huynh initiated coverage of GSK (GSK) with a Sector Perform rating and 1,975 GBp price target The shares are up 30% over the past year reflecting…
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The t...
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Uber, GSK, ShopRite and oda foreign companies wey don comot for Nigeria - why dem dey leave?
Nigerians wake up on Wednesday to hear di tori say online ride hailing company Uber dey close down dia business for Nigeria and dey comot for di kontri. Uber say demdey comot from Nigeria afta spendin...
HCM Looks 9.3% Undervalued on GF Value⢠After Licensing Deal with GSK
HCM Looks 9.3% Undervalued on GF Value⢠After Licensing Deal with GSK
Hutchmed, GSK enter HMPL-A830 commercialization agreement
Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK (GSK), granting the GSK subsidiary worldwide ri...
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker ...
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
(RTTNews) - HUTCHMED (China) Limited (HCM), a precision oncology-focused company, on Thursday announced that its subsidiary HUTCHMED Limited has entered into an exclusive development and license agree...
GSK Looks 10.0% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 10.0% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK's MRNA Flu Vaccine Candidate Advances To Phase III Trial
(RTTNews) - GSK plc (GSK) will advance its investigational mRNA seasonal flu vaccine candidate into Phase III testing after Phase II results showed stronger immune responses compared to standard and h...
GSK Looks 10.1% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 10.1% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK to advance mRNA flu vaccine to late-stage trial
GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than curr...
Noteworthy ETF Outflows: FENI, GSK, UL, SHEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
GSK: ViiV Healthcare Secures FDA Approval For Tivicay PD In Young Children With HIV
(RTTNews) - ViiV Healthcare, a specialist HIV company majority-owned by GSK plc., (GSK), announced that the U.S. FDA has approved Tivicay PD for use in combination with other antiretroviral agents in ...
GSK Looks 13.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 13.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 14.4% Overvalued on GF Value⢠Amid New HIV Treatment Approval
GSK Looks 14.4% Overvalued on GF Value⢠Amid New HIV Treatment Approval
GSK’s ViiV Healthcare announces FDA approval of Tivicay PD
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced that the U.S. FDA has approved Tivicay PD, for use in combination…
Noetik Achieves First Milestone in Landmark GSK Collaboration
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--Noetik achieves first milestone in landmark GSK collaboration.
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on GSK (GSK) to 1,900 GBp from 1,750 GBp and keeps an Underweight rating on the shares.
AnaptysBio price target lowered to $70 from $75 at TD Cowen
TD Cowen lowered the firm’s price target on AnaptysBio (ANAB) to $70 from $75 and keeps a Buy rating on the shares. The firm updated its model after GSK (GSK)…
GSK shares drift despite drug approvals boost
Drugs giant GSK saw its shares drift lower despite announcing progress on two key products yesterday.
GSK Looks 15.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 15.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 15.2% Overvalued on GF Value⢠Amid Solid Dividend Fundamentals
GSK Looks 15.2% Overvalued on GF Value⢠Amid Solid Dividend Fundamentals